ROBERT E. CONWAY - Corporate Board Profile

Oruka Therapeutics, Inc.

Filing Date	Source Excerpt
2014-04-15	Mr. Conway, age 60, was appointed to the ARCA Board of Directors in September 2013. ... Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and education supplies company. ... The Audit Committee is currently composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Woosley. ... The Compensation Committee is currently composed of three directors: Mr. Robert Conway, Dr. Linda Grais (chair) and Dr. Raymond Woosley. ... The Nominating and Corporate Governance Committee is currently composed of three directors, Dr. Grais, Mr. Mitchell and Dr. Woosley. ... Mr. Conway joined the Company 27s Board of Directors on September 3, 2013. ... The aggregate number of option awards outstanding at December 31, 2013 for Mr. Conway was 18,608, of which 3,939 shares were fully vested. ... The following table shows for the fiscal year ended December 31, 2013 certain information with respect to the compensation of all non-employee directors of the Company: ... Robert E. Conway ... Total($) 23,951.
2015-04-14	Mr. Conway, age 61, was appointed to the ARCA Board of Directors in September 2013. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array Biopharma, a publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the Boards of Directors of PRA International, Inc., which was a public company for a portion of his tenure there, and eResearch Technology, Inc., a private company. Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC. Mr. Conway received a B.S. in accounting from Marquette University in 1976. He is an appropriate nominee to the Company’s Board of Directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance. Director Compensation for fiscal 2014: $61,804.
2016-04-27	Mr. Conway, age 62, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... The Audit Committee is currently composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Woosley. ... The Compensation Committee is currently composed of three directors: Mr. Robert Conway, Dr. Linda Grais (chair) and Dr. Raymond Woosley. ... Director Compensation for fiscal 2015: Robert E. Conway Fees Earned or Paid in Cash ($) 65,000, Option Awards ($) 3,645, Total ($) 68,645.
2017-04-21	Mr. Conway, age 63, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... In the fiscal year ended December 31, 2016, the Audit Committee was composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Woosley. ... The Compensation Committee is currently composed of three directors: Mr. Conway, Dr. Grais (chair) and Dr. Woosley. ... Director Compensation for Mr. Conway for fiscal 2016 was $97,479.
2018-04-18	Mr. Conway, age 64, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr. Conway continues to serve on the board of directors following such combination. Mr. Conway also serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Bracket, Inc. Mr. Conway received a B.S. in accounting from Marquette University in 1976. We believe Mr. Conway is an appropriate member of the Board of Directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance. Director Compensation For fiscal year ended December 31, 2017, Mr. Conway received $80,000 in fees earned or paid in cash and $12,220 in option awards, totaling $92,220.
2018-09-20	The following table sets forth certain information regarding the ownership of the Companys Common Stock as of the August 31, 2018, by: (i) each director and nominee for director, (ii) each of our named executive officers, (iii) all executive officers and directors of the Company as a group, and (iv) all those known by the Company to be beneficial owners of more than five percent of its Common Stock.
2019-10-25	Mr. Conway, age 65, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... The Audit Committee is composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Grais. ... The Compensation Committee is currently composed of three directors: Mr. Conway, Dr. Grais (chair) and Dr. Woosley. ... Director Compensation for Fiscal 2018 ... Robert E. Conway ... $84,640.
2020-10-28	Robert E. Conway Mr. Conway, age 66, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... The Audit Committee is composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Grais. ... Director Compensation for Fiscal 2019 shows Mr. Conway received $80,000 in cash fees.
2022-11-03	Mr. Conway, age 68, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. ... The Audit Committee was composed of three directors: Mr. Conway (chair), Mr. Mitchell and Dr. Grais. ... The Compensation Committee of the Board of Directors, or the Compensation Committee, is currently composed of three directors: Mr. Conway, Dr. Grais (chair) and Dr. Woosley. ... In 2022, the Board of Directors established a Special Committee ... The Special Committee includes ARCA Board Chairman Robert E. Conway (chair) ... Director Compensation for Fiscal 2021 ... Robert E. Conway ... Fees Earned or Paid in Cash ($) 87,500 ... Option Awards ($) 39,187 ... Total ($) 126,687.
2023-12-19	Mr. Conway, age 69, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors since 2014. ... As of December 31, 2022, Mr. Conway was Chair of the Audit Committee and member of the Compensation Committee. Director compensation for 2022 was $101,336.